Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 15/20 | 0.84 |
| ▸ | FNTB | P49356 | 15/20 | 0.84 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8750233 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL14169145 | 0.87 | FNTA (0.80) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL29450593 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1KMT2A | |
| SCHEMBL25722631 | 0.81 | FNTA (0.64) | FNTAFNTBPGGT1BTDP1HPGD | |
| SCHEMBL8750304 | 0.77 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL16136603 | 0.71 | FNTA (0.67) | FNTAFNTBPGGT1BTDP1CA1 | |
| SCHEMBL8097481 | 0.71 | FNTA (0.67) | FNTAFNTBPGGT1BTDP1CA1 | |
| SCHEMBL8623007 | 0.71 | FNTA (0.67) | FNTAFNTBPGGT1BTDP1CA1 | |
| SCHEMBL10038916 | 0.71 | FNTA (0.67) | FNTAFNTBPGGT1BTDP1CA1 | |
| SCHEMBL8365606 | 0.69 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | FNTA, GGPS1, FNTB | FNTA 1/4885FNTB 3/4885PGGT1B 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.